{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:29:58Z","timestamp":1793780998180,"version":"4.6.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.diabet.2026.101794","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:20:15Z","timestamp":1790292015000},"page":"101794","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes"],"prefix":"10.1016","volume":"52","author":[{"given":"Haitham","family":"Abu Khadija","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Alnees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kareem","family":"Ibraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9578-1105","authenticated-orcid":false,"given":"Taha","family":"Z\u2024 Makhlouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5615-4066","authenticated-orcid":false,"given":"Ramon","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duha","family":"Najajra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Twito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8378-2903","authenticated-orcid":false,"given":"Tal","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0613-0892","authenticated-orcid":false,"given":"Alena","family":"Kirzhner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2026.101794_bib0002","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.2337\/dc23-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101794_bib0003","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s13300-024-01606-6","article-title":"Epidemiology and burden of peripheral artery disease in people with type 2 diabetes: a systematic literature review","volume":"15","author":"Verma","year":"2024","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.diabet.2026.101794_bib0004","unstructured":"GLP1RAs in clinical practice: therapeutic advances and safety perspectives. American College of Cardiology. Accessed: Aug. 28, 2026. [Online]. Available: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2024\/04\/15\/11\/19\/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2024%2f04%2f15%2f11%2f19%2fglp1ras-in-clinical-practice."},{"key":"10.1016\/j.diabet.2026.101794_bib0005","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2026.101794_bib0006","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.amjcard.2025.09.039","article-title":"GLP-1 receptor agonists and cardiovascular outcomes in adults with diabetes and peripheral artery disease: an updated systematic review and meta-analysis","volume":"258","author":"Shuja","year":"2026","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.diabet.2026.101794_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112982","article-title":"Risk of lower extremity complications with GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in peripheral artery disease","volume":"230","author":"Hong","year":"2025","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.diabet.2026.101794_bib0008","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2026.101794_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10741-024-10450-6","article-title":"GLP-1 receptor agonists as promising anti-inflammatory agents in heart failure with preserved ejection fraction","volume":"30","author":"Bonfioli","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.diabet.2026.101794_bib0010","doi-asserted-by":"crossref","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","article-title":"GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage","volume":"326","author":"Park","year":"2024","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.diabet.2026.101794_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2026.113271","article-title":"GLP-1\u2013based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies","volume":"236","author":"Boccatonda","year":"2026","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.diabet.2026.101794_bib0012","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/dc18-1094","article-title":"The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER Trial","volume":"41","author":"Dhatariya","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2026.101794_bib0013","first-page":"1024","article-title":"Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease","volume":"82","author":"Go","year":"2025","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.diabet.2026.101794_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112083","article-title":"Tirzepatide and major adverse limb events: insights from a multicenter real-world analysis in PAD and diabetes patients","volume":"222","author":"Wu","year":"2025","journal-title":"Diabetes Res Clin Pr"},{"key":"10.1016\/j.diabet.2026.101794_bib0015","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00125-021-05497-1","article-title":"Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors","volume":"64","author":"Lin","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabet.2026.101794_bib0016","author":"Daniel"},{"key":"10.1016\/j.diabet.2026.101794_bib0017","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.avsg.2025.08.013","article-title":"GLP-1 receptor agonists associated with improved survival after infrainguinal bypass in diabetic patients","volume":"121","author":"Yehualashet","year":"2025","journal-title":"Ann Vasc Surg"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362600073X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S126236362600073X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:55:10Z","timestamp":1793778910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S126236362600073X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S126236362600073X"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101794","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2026.101794","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101794"}}